Bioorganic & medicinal chemistry · 2011
Discovery of new orally active prostaglandin D2 receptor antagonists.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Iwahashi Maki, Naganawa Atsushi, Kinoshita Atsushi, Shimabukuro Atsushi, Nishiyama Toshihiko, Ogawa Seiji, Matsunaga Yoko, Tsukamoto Kohki, Okada Yutaka, Matsumoto Ryoji, Nambu Fumio, Oumi Rie, Odagaki Yoshihiko, Katagi Jun, Yano Koji, Tani Kousuke, Nakai Hisao, Toda Masaaki
Аннотация
To identify an orally available drug candidate, a series of 3-benzoylaminophenylacetic acids were synthesized and evaluated as prostaglandin D(2) (PGD(2)) receptor antagonists. Some of the compounds tested were found to exhibit excellent inhibitory activity against cAMP accumulation in human platelet rich plasma (hPRP), which is one of the indexes of DP antagonism. The optimization process including improvement of the physicochemical properties such as solubility, which may result in an improved pharmacokinetic (PK) profile, is presented. Optimized compounds were studied for their pharmacokinetics and in vivo potential. A structure-activity relationship study is also presented. Some of the test compounds were found to have in vivo efficacy towards the inhibition of PGD(2)-induced and OVA-induced vascular permeability in guinea pig conjunctiva.